Business Context and Reporting Period
Company: ILLUMINA, INC.
Filing Type: Form 10-Q (Quarterly Report)
Period Ended: September 28, 2003
Business Overview: Illumina develops next-generation tools for large-scale genetic analysis, including the BeadArray technology platform, oligonucleotide manufacturing (Oligator), and SNP genotyping services. The company is in an early commercialization stage, focusing on life sciences and pharmaceutical markets.
Key Financial Metrics
| Metric (in thousands) | 3 Months Ended Sept 28, 2003 |
9 Months Ended Sept 28, 2003 |
9 Months Ended Sept 29, 2002 |
|---|---|---|---|
| Total Revenue | $8,249 | $17,294 | $6,154 |
| Net Loss | $(5,511) | $(23,063) | $(32,715) |
| Net Loss Per Share (Basic/Diluted) | $(0.17) | $(0.72) | $(1.06) |
| Cash and Cash Equivalents | $9,989 | $9,989 (End of Period) | $1,185 (End of Period) |
| Total Investments (Available for Sale) | $28,859 | $28,859 (End of Period) | $51,727 (End of Period) |
| Restricted Cash/Investments | $12,360 | $12,360 (End of Period) | $12,530 (End of Period) |
| Long-Term Debt | $25,090 | $25,090 (End of Period) | $25,367 (End of Period) |
| Accrued Litigation Judgment | $8,469 | $8,469 (End of Period) | $8,052 (End of Period) |
Gross Margins: Product and service gross margins were 65% for the three months ended Sept 28, 2003, and 56% for the nine-month period, compared to 60% and 54% respectively in the prior year periods.
Cash Flow (9 Months 2003): Net cash used in operating activities was $12.8 million. Net cash provided by investing activities was $20.5 million, primarily due to maturities of investment securities. Net cash provided by financing activities was $0.3 million.
Material Changes vs. Prior Period
- Revenue Growth: Total revenue increased significantly to $17.3 million for the nine months ended Sept 28, 2003, compared to $6.2 million in the prior year period. This was driven by the sale of four BeadLab SNP genotyping systems and related consumables.
- Product Revenue: Product revenue surged to $10.6 million (9 months 2003) from $2.9 million (9 months 2002), reflecting the commercialization of the BeadLab system.
- Service Revenue: SNP genotyping service revenue grew to $4.4 million (9 months 2003) from $1.2 million (9 months 2002).
- Operating Expenses: Selling, general, and administrative (SG&A) expenses increased to $13.8 million (9 months 2003) from $6.3 million (9 months 2002), largely due to higher legal fees related to the Applied Biosystems dispute and expanded sales/marketing efforts.
- Net Loss Improvement: Net loss narrowed to $23.1 million (9 months 2003) from $32.7 million (9 months 2002), primarily due to the absence of the $7.9 million litigation judgment charge recorded in the prior year period.
Guidance, Outlook, Risks, and Contingencies
Outlook and Guidance: Management expects to continue incurring net losses and negative cash flow for the foreseeable future. Current cash, investments, and grant funding are projected to be sufficient to fund operations for at least 18 to 24 months. The company anticipates significant increases in operating expenses as it expands sales and marketing infrastructure.
Material Risks and Contingencies:
- Applied Biosystems Litigation: A significant legal dispute exists with Applied Biosystems regarding a joint development agreement. Applied Biosystems has filed a patent infringement suit seeking damages and an injunction, and has demanded arbitration alleging breach of contract, seeking $30 million in damages and disgorgement of revenues. Illumina has filed counterclaims alleging breach of contract and fraudulent inducement. The outcome is uncertain and could materially adversely affect the business.
- Employment Litigation: A $7.7 million judgment was recorded in 2002 regarding a termination-of-employment lawsuit. Illumina is appealing the verdict. Approximately $12.5 million of marketable securities are restricted as collateral for a surety bond related to this appeal.
- Deferred Revenue: $10 million in non-refundable research funding from Applied Biosystems is recorded as deferred revenue and will not be recognized until the legal status of the collaboration is resolved.
- Market Acceptance: Success depends on the adoption of new technologies (BeadArray, BeadChip) in emerging markets. Competition is intense, and the company has limited commercial sales history for its systems.
Key Facts for Investor Verification
- Liquidity Position: Verify the total available liquidity of approximately $51.2 million (cash, equivalents, and investments), noting that $12.4 million is restricted due to the employment litigation appeal.
- Legal Exposure: Assess the potential financial impact of the Applied Biosystems dispute, which involves claims of patent infringement, breach of contract, and potential disgorgement of all genotyping system and service revenues.
- Revenue Concentration: Confirm the reliance on large, individual transactions (e.g., BeadLab system sales) which may cause significant quarter-to-quarter revenue volatility.
- Debt Obligations: Review the $26 million mortgage on corporate facilities, which includes a balloon payment of $21.2 million due in 2012.
- Profitability Path: Evaluate the company's ability to scale revenue sufficiently to offset rising SG&A and R&D costs, given an accumulated deficit of $113.5 million as of September 28, 2003.